Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.32), $0.04 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $27.23 million versus the consensus estimate of $26.86 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.